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Chronic kidney disease (CKD) is a key cause of hypertension
and a potent independent risk for cardiovascular disease.
Epidemiological studies suggest a strong genetic component
determining susceptibility for renal disease and, by inference,
the associated cardiovascular risk. With a subtotal
nephrectomy model of kidney disease, we found the 129S6
mouse strain to be very susceptible to the development of
hypertension, albuminuria, and kidney injury, whereas the
C57BL/6 strain is relatively resistant. Accordingly, we set out
to map quantitative trait loci conferring susceptibility to
hypertension and albuminuria using this model with F2 mice.
We found significant linkage of the blood pressure trait to
two loci. At D11Mit143, mice homozygous for the 129S6
allele had significantly higher systolic blood pressure than
mice heterozygous or homozygous for the C57BL/6 allele.
Similarly, at D1Mit308, there was an excellent correlation
between genotype and the blood pressure phenotype.
The effect of the chromosome 11 locus was verified with a
separate cohort of F2 mice. For the albuminuria trait, a
significant locus was found at D11Mit143, which overlaps the
blood pressure trait locus. Our studies have identified a
region spanning B8 cM on mouse chromosome 11 that is
associated with susceptibility to hypertension and
albuminuria in CKD.
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Chronic kidney disease (CKD) is defined as a persistent
reduction in glomerular filtration rate and/or the presence of
albuminuria.1 CKD is highly prevalent, with recent estimates
suggesting that more than 18 million people in the United
States are affected.2 One consequence of CKD is progression
to end-stage renal disease requiring renal replacement
therapy including dialysis and/or renal transplantation.
However, perhaps more important from a public health
standpoint are emerging data showing that CKD is a
powerful risk factor for the development of cardiovascular
disease.3–8 Hypertension is a risk factor for cardiovascular
and kidney diseases, and is also a common complication of
CKD. The prevalence of hypertension in patients with CKD is
three to four times that of the general population, affecting
approximately 50–75% of individuals with GFRo60 ml/min/
1.73 m2 (CKD stages 3–5).1
There is growing evidence that inherited factors contribute
to the progression of CKD. For example, African Americans
with hypertension are seven times more likely to develop
end-stage renal disease than Caucasians.2 Similarly, in
diabetic nephropathy, African Americans, Mexican Amer-
icans, and American Indians have a disproportionately higher
incidence of end-stage renal disease than Caucasians.9,10
There have also been many reports of familial clustering of
cases of end-stage renal disease and diabetic nephro-
pathy.11–16 Population-based and family-based epidemiological
studies support the premise that susceptibility to develop-
ment and progression of kidney disease and its complications
has a heritable component. However, demonstration of
specific genetic variants that determine susceptibility to
development and progression of CKD and its associated
cardiovascular risks have been elusive.
Various animal models of CKD that resemble the disease
process in humans have been widely used to attempt to
unravel the mechanisms that cause progression of kidney
injury. One of these models is subtotal nephrectomy. The
surgical excision of renal mass is thought to recapitulate the
maladaptive elevation of the single-nephron glomerular
hyperfiltration process17 in the remaining nephrons in
humans, regardless of the primary etiology of kidney injury.
This simple model in rats results in a number of features of
CKD in humans, including hypertension, albuminuria, and
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glomerulosclerosis,18 and established the efficacy of ACE
inhibitors that is now widely used clinically in the prevention
of progression of kidney disease.19,20 However, responses to
subtotal nephrectomy are variable in mice and previous
studies have suggested that common strains of laboratory
mice have varying susceptibilities to the development of
hypertension, albuminuria, and kidney injury after renal
ablation.21,22 The purpose of this study was to characterize
the effects of genetic background on the manifestations of
CKD in the mouse and to localize these modifying genes to
specific chromosomal segments.
RESULTS
Genetic effects that enhance susceptibility to hypertension in
CKD
To determine whether genetic factors contribute to the
severity and manifestations of CKD, we examined responses
to subtotal nephrectomy in two common inbred laboratory
strains, 129S6 (formerly 129/SvEv), and C57BL/6. As
hypertension is commonly the first clinically detected
cardiovascular consequence of CKD and the source of
significant morbidity in CKD patients, we first examined
blood pressure responses using tail-cuff manometry in the
7th to 10th week after subtotal nephrectomy. Baseline systolic
blood pressures were similar between 129S6 and C57BL/6
mice (10473, n¼ 20 vs 10372 mm Hg, n¼ 20; P¼NS).
After subtotal nephrectomy, blood pressures increased in
both strains compared to baseline (Po0.0005), but were
significantly higher in the 129S6 mice (143716 mm Hg,
n¼ 16) than the B6 mice (127711 mm Hg, n¼ 19,
P¼ 0.004) (Figure 1).
We next compared blood pressures in the F1
(129S6C57BL/6) cross with those of the parental lines.
Baseline systolic blood pressures of the F1 mice were similar
to those of the parental lines (10373 mm Hg, P¼NS). After
subtotal nephrectomy, blood pressures in the F1 mice were
virtually identical to those of the C57BL/6 mice
(125715 mm Hg, n¼ 20; P¼NS) (Figure 1). By analysis
of variance (ANOVA), blood pressures were significantly
higher in the 129S6 group after subtotal nephrectomy
compared to either the C57BL/6 (26.94, 3.06) or F1
(28.91, 6.83) group (P¼ 0.001). This suggests that there
are genes with recessive effects on the 129S6 background that
confer susceptibility to development of hypertension after
reduction of renal mass.
Genetic effects that enhance susceptibility to albuminuria
and kidney injury in CKD
As albuminuria is a key marker of kidney injury, we
measured urinary albumin excretion, expressed as albumin/
creatinine (A/C) ratio, in the three experimental groups. In
previous studies in mice23 and in our own experience, the
A/C ratio correlates well with 24-h urinary albumin excretion.
As with blood pressure, we found significant strain
differences in the extent of albuminuria after subtotal
nephrectomy. The 129S6 mice had the highest levels of A/C
ratio (3667112 mg/mg), followed by the C57BL/6 mice
(174736 mg/mg) and F1 mice (4478 mg/mg), Po0.004
(ANOVA, one-way) (Figure 2).
We next compared kidney histopathology between the
experimental groups. Thirteen weeks after subtotal nephrec-
tomy, 129S6 mice developed kidney injury characterized by
glomerulosclerosis and tubulo-interstitial inflammation char-
acterized by lymphocytic infiltration (Figure 3a and b). By
contrast, the extent of renal pathology was less severe in the
C57BL/6 animals (Figure 3c and d). The severity of the
pathological changes was also quantitated by our renal
pathologist masked to the experimental groups. As shown in
Figure 4, the extent of kidney pathology was significantly
worse in the 129S6 group than the C57BL/6 mice (1978,
n¼ 16 vs 1373, n¼ 19; P¼ 0.02). On the other hand, the
F1 animals were significantly more resistant to renal injury than
either parental line (severity score: 872, n¼ 20; Po0.0005
by ANOVA, one-way). Taken together, these studies suggest
that there are strain-specific genetic factors between the
129S6 and C57BL/6 lines with strong actions to influence the
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Figure 1 | Systolic blood pressure at baseline and after subtotal
nephrectomy. Systolic blood pressure was measured by tail-cuff.
At baseline, blood pressures were similar between 129S6 (white bar),
C57BL/6 (black bar), and F1 (129S6C57BL/6) (gray bar) mice. After
subtotal nephrectomy, blood pressures increased in all groups
compared to baseline, but were significantly higher in the 129S6
strain compared to C57BL/6 and F1 mice, *P¼ 0.001, ANOVA,
one-way. Values are expressed as mean7s.e.m.
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Figure 2 | A/C ratios after subtotal nephrectomy. 129S6 mice have
significantly higher A/C ratios than C57BL/6 and F1 mice. Values are
expressed as mean7s.d. 129S6 (white bar) 3667112 mg/mg, n¼ 16;
C57BL/6 (black bar) 174736, n¼ 19; F1 (129S6C57BL/6) (gray bar)
4478, n¼ 20. P¼o0.004, ANOVA, one-way.
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development of hypertension, proteinuria, and kidney injury
in this model of CKD.
Linkage of CKD-associated hypertension to chromosomes
11 and 1
Based on our observations in the parental strains, we first set
out to map the quantitative trait loci (QTLs) conferring
susceptibility to hypertension in this model of CKD. To this
end, we performed subtotal nephrectomy on F2 mice, and
began whole genome scan using 44 consecutive animals. Our
scan revealed significant linkage of the blood pressure trait to
two loci, one on chromosome 1, Ckdbp1 (CKD Blood
Pressure Locus 1), and one on chromosome 11, Ckdbp2, as
shown in Figure 5a.
By interval mapping (Figure 5a), at the Ckdbp2 locus on
chromosome 11, the likelihood ratio statistic (LRS) score
approached highly significant linkage criteria, LRS 22
(logarithm of the odds score B4.8), and exceeded signi-
ficance at the Ckdbp1 locus on chromosome 1, LRS 17.3
(logarithm of the odds score B3.8). Ckdbp2 and Ckdbp1
explain 39 and 21% of the variance for blood pressure,
respectively. We next compared blood pressure levels between
animals of each genotype at the D11Mit143 marker on
chromosome 11. As shown in Figure 5b, mice homozygous at
D11Mit143 for the 129S6 allele had significantly higher blood
pressures (169717 mm Hg; n¼ 9) than mice that were
heterozygous (144711 mm Hg; n¼ 26) or homozygous for
the C57BL/6 allele (144712 mm Hg; n¼ 9; Po0.0005). This
pattern was similar for Ckdbp1 on chromosome 1. Mice
homozygous for the 129S6 allele at D1Mit308 had signi-
ficantly higher blood pressures (167719 mm Hg) than
heterozygotes (146714 mm Hg) or mice that were homo-
zygous for the C57BL/6 allele (14278 mm Hg; Po0.0005,
graph not shown). Thus, within both QTLs, homozygosity
for the 129S6 allele was associated with a significant increase
in blood pressure.
We next performed interaction mapping and found no
interaction between these two QTLs even at significance
threshold set at the lowest level of stringency of P¼ 0.05.
Thus, we have identified two QTLs (Ckdbp1 and Ckdbp2)
that are independently associated with susceptibility for the
development of hypertension after subtotal nephrectomy,
both originating from the 129S6 background.
A QTL for albuminuria in model of CKD
After subtotal nephrectomy, we found that 129S6 mice were
much more susceptible to development of albuminuria than
C57BL/6 mice, while F1 animals were relatively resistant. To
explore this further, we carried out a genome-wide scan for
albuminuria, expressed as A/C ratio, in the same F2 progeny.
This analysis revealed only one significant QTL for
albuminuria, which is located on chromosome 11. At marker
D11Mit143, the LRS was 11.4. This locus overlaps Ckdbp2
and interval mapping on chromosome 11 for A/C ratio
reveals a curve that is very similar to that for the blood
pressure trait (Figure 6a). We next compared A/C ratios
between animals of each genotype at the D11Mit143 marker
on chromosome 11. As shown in Figure 6b, mice homo-
zygous at D11Mit143 for the 129S6 allele had significantly
higher A/C ratio blood pressures (3067140 mg/mg) than
mice that were homozygous (105769 mg/mg) or hetero-
zygous for the C57BL/6 allele (71723 mg/mg), P¼ 0.02.
Genome-wide scan for kidney injury
Using kidney pathology scores as another measure of kidney
injury, we have also found a suggestive locus on chromosome
2, D2Mit285, that is associated with susceptibility to
glomerulosclerosis with an LRS of 13.7. We suspect that the
limited range of severity of pathological lesions in this cohort
limited our ability to precisely define and confirm this QTL.
We anticipate that with more animals, we will be able to find
significant linkage for this trait.
Figure 3 | Kidney histology 13 weeks after subtotal nephrectomy.
129S6 mice develop tubulo-interstitial inflammatory changes with
lymphocytic infiltration (a ( 10)) and severe glomerulosclerosis
characterized by marked mesangial matrix deposition (b ( 40)).
C57BL/6 mice have negligible tubulo-interstitial disease (c ( 10))
and develop only mild mesangial expansion and hypercellularity of
the glomeruli (d (40 )).
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Figure 4 | Total kidney injury scores. Values are expressed as
mean7s.d. 129S6 (white bar) 1978, n¼ 16; C57BL/6 (black bar)
1373, n¼ 19; F1 (129S6C57BL/6) (gray bar) 872, n¼ 20. P¼ 0.02
for 129S6 vs C57BL/6; Po0.005 for F1 vs 129S6 and C57BL/6, ANOVA,
one-way.
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Association study of Ckdbp2
Based on the genome scan, Ckdbp2 accounts for 39% of the
variance in blood pressure. To verify this strong effect, we
compared genotypes vs blood pressure specifically at the
Ckdbp2 locus in a separate cohort of 27 F2 animals. The
association of this locus to blood pressure response was
significantly replicated in this second cohort. At D11Mit143,
mice homozygous for the 129S6 allele had significantly
higher blood pressures (152713 mm Hg) than those
homozygous for the C57BL/6 allele (13779 mm Hg)
(P¼ 0.02). Blood pressures in mice heterozygous
(14478 mm Hg) were not statistically different from those
homozygous for the C57BL/6 allele, P40.2. Taken together,
the results of two separate cohorts demonstrate that Ckdbp2
has a robust effect on blood pressure response to loss of
nephron mass. At Ckdbp1, there was again a trend toward
higher blood pressure in mice homozygous for the 129S6
allele in this second cohort, but the association was not
statistically significant. Efforts are underway to perform
whole genome scan for the combined cohorts using dense
single nucleotide polymorphic analysis to fine-map the blood
pressure trait.
DISCUSSION
Subtotal nephrectomy in rodents is a well-established model
of progressive kidney disease. In rats, this simple model
recapitulates a number of features of CKD in humans
including hypertension, albuminuria, and glomerular sclero-
sis.17,18 The model also has proven utility in identifying
therapeutic approaches, such as the use of angiotensin-
converting enzyme inhibitors, which were later found to be
applicable to humans with CKD in numerous clinical
trials.19,20 The remnant kidney model has been used in
various species, including dogs, cats, rabbits, baboons, and
most extensively in rats.21 Although utilization of this model
in mice has been somewhat limited, previous studies
suggested a variable susceptibility to renal injury between
different strains of mice. For example, the C57BL/6 strain was
reported to be resistant to the development of proteinuria
after subtotal renal ablation.21 Moreover, in a genetic model
of reduced nephron mass, C57BL/6 mice were resistant to
glomerulosclerosis, whereas mice from the ROP strain
developed severe glomerular scarring.24 Similarly, Fogo and
co-workers22 identified robust phenotypic differences in the
responses to subtotal nephrectomy between C57BL/6 and
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Figure 5 | Genome-wide scan and mapping for blood pressure trait. (a) Linkage analysis. Interval maps of each of the autosomes for
blood pressure trait are shown. Statistical significance was determined using data permutation tests and the P¼ 0.05 and 0.001 thresholds.
Only two regions of the genome, one on chromosome 1 and one on chromosome 11, passed the P¼ 0.05 threshold for blood pressure
trait. (b) Blood pressure vs genotype at D11Mit143. Values are expressed as mean7s.d. Homozygous for 129S6 allele (129)(white bar)
169719 mm Hg, homozygous for C57BL/6 allele (black bar) (B6) 144712 mm Hg, and heterozygous (gray bar) (129/B6) 144711 mm Hg.
Values are expressed as mean7s.d. Po0.0005, ANOVA, one-way.
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129/Sv strains. In the current study, we also found that 129S6
mice develop marked hypertension, proteinuria, and glome-
rulosclerosis after subtotal nephrectomy, whereas C57BL/6
mice are relatively resistant to renal injury, developing only
moderate increases in blood pressure and albumin excretion.
Furthermore, with subtotal nephrectomy, F1 mice have only
modest increases in blood pressure, similar to the C57BL/6
line, and are significantly more resistant to the development
of albuminuria and renal pathology than either of the
parental strains.
Traditional QTL mapping relies on genetic ‘outliers’ that
operate within the normal physiologic range, and typically
relies on very large numbers of animals. Using our model, a
surgical sensitizer to mimic the clinical pathological process
of CKD, we are pushing the phenotype into the pathologic
range and we are mapping only those genetic factors that
strongly influence or modify the outcome. In this light, the
genetic factor(s) being investigated are acting similarly to
modifier loci, such as those that modify the phenotype in a
knockout or transgenic mouse. In our case, we have
employed a surgical rather than genetic sensitizer to create
CKD, but the principle remains the same. Using this
approach, we have identified two QTLs for hypertension.
One of these, Ckdbp1, is located on chromosome 1 between
positions 43 and 73 cM. Previous studies have identified blood
pressure QTLs on mouse chromosome 1.25–27 Our locus,
Ckdbp1, is centered at 62.1 cM and appears to lie between these
two previously independently identified QTLs.25–27
The QTL Ckdbp2 has robust effects on blood pressure, as
demonstrated by reproducible results in our association
study in an independent cohort of F2 mice. It is located in an
8 cM region defined by markers D11Mit86 (28 cM, 53.8 Mb)
and D11Mit177 (36 cM, 64.8 Mb). This region overlaps a
previously reported blood pressure QTL, Abbp4, on mouse
chromosome 11 that conferred a 7–12 mm Hg increase in
blood pressure in a genome-wide screen for blood pressure
QTLs between two distinct and unmanipulated inbred
strains.26 Comparative mapping28 demonstrates that the
distal segment of mouse chromosome 11 is syntenic with
the distal segment of rat chromosome 10 where multiple
blood pressure QTLs have been reported in several
independent studies. This distal segment is also syntenic
with the mid-segment of human chromosome 17 where
genetic susceptibility for essential hypertension, HYT1, in
humans has also been reported.29,30 Of note, WNK4,
mutations of which cause pseudohypoaldosteronism type II
and hypertension in humans, lies within this region.31
Although our candidate region is slightly above the syntenic
region across the three species, its location just above the
blood pressure QTL region on human chromosome 17 and
its proximity to the conserved syntenic region for blood
pressure QTLs in human and rat suggest some overlap with
previously identified hypertension QTLs. Moreover, this is
the first documented linkage of this region in hypertension
associated with CKD. Interestingly, this locus is immediately
adjacent to the locus on chromosome 11 that is associated
with compensatory renal hypertrophy in mice after unilateral
nephrectomy.32
Although the absolute ranges for blood pressure from the
two distinct cohorts are slightly different, the difference in
allelic effects on blood pressure at Ckdbp2 in both cohorts is
the same at 15 mm Hg. This magnitude of difference is
almost identical to the difference between the parental strains
(16 mm Hg). The variation in the absolute blood pressure
ranges in the cohorts and the parental and F1 strains likely
reflects seasonal variations in blood pressures that are
commonly observed in mice, as these cohorts and the
parental strains were studied at different time points. It is also
possible that this reflects the complexity of gene interactions.
As there are potential confounding effects of sex steroid
hormones, we determined whether sex may influence blood
pressure in our F2 cohorts. We examined the cohorts
separately and together, and found that systolic blood
pressures were only 3–5 mm Hg higher in males vs females
after subtotal nephrectomy, but this was not statistically
significant (P40.3). Furthermore, there was no apparent
impact of sex at the Ckdbp2 locus when the groups were
analyzed based on sex and genotypes.
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Figure 6 | Interval mapping of chromosome 11 for blood pressure
and albuminuria. (a) Multipoint linkage analysis of microsatellite
markers on chromosome 11 for blood pressure and albuminuria.
Interval mapping identified a strong modifier locus for blood
pressure at D11Mit143 (Ckdbp2), map distance 8 cM, with an LRS
of 22 (logarithm of the odds score B4.8). Whole genome scan for
albuminuria trait revealed only one significant locus, also at
D11Mit143 (LRS 11.4), with very similar interval mapping as for blood
pressure. (b) A/C ratios vs genotype at D11Mit143. Values are
expressed as mean7s.d. Homozygous for 129S6 allele (129)
(white bar) 3067140 mg/mg, homozygous for C57BL/6 allele
(black bar) (B6) 105759mg/mg, and heterozygous (gray bar) (129/B6)
71723 mg/mg. P¼ 0.02, ANOVA, one-way.
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Our genome-wide scan for albuminuria, expressed as A/C
ratio, reveals the same locus found for Ckdbp2, with very
similar interval mapping curve. This is the first documented
linkage on mouse chromosome 11 for albuminuria. In
humans and in other models, albuminuria can be associated
with and secondary to increased blood pressure. In our
F2 cohort, there was a significant positive correlation between
A/C ratio and blood pressure, R2¼ 53.2%, Po0.0005, suggest-
ing a causal association. Our studies are consistent with
previous work, suggesting that the 129 strain may be more
susceptible to the development of kidney injury after partial
renal ablation.22 This susceptibility may also extend to other
models of kidney disease. Our finding of a common QTL
derived from the 129S6 background that is associated with
blood pressure and albuminuria suggests that the susceptibility
to renal injury on the 129S6 background may be driven by a
propensity to develop hypertension after loss of nephron mass.
On the other hand, our genome-wide scan for patho-
logically defined kidney injury revealed a suggestive locus on
chromosome 2 (LRS of 13.7) that is associated with
glomerulosclerosis. This locus is clearly distinct from either
of the blood pressure QTLs, suggesting that there may be
genetic components determining susceptibility to kidney
injury that are distinct from hypertension. However, the
limited range of severity of pathological lesions in this cohort
limited our ability to precisely define and confirm this QTL.
A larger cohort and more robust scoring system that allows a
wider range of scores may enable a greater likelihood of
obtaining association with chromosomal regions. Alterna-
tively, haplotype analysis using the extremes of one to two
standard deviations as ‘affected’ vs ‘unaffected’ may also be of
potential value.
In summary, the study we report represents a novel
approach to the use of a mouse model of CKD to find
modifier genes and their role in the progression of kidney
disease and its systemic consequences. Defining the genetic
variants that confer susceptibility to CKD and its cardiovas-
cular effects will at the very least identify potential
mechanisms to explain the detrimental effects of CKD on
cardiovascular risks. They also provide the potential oppor-
tunity to identify candidate genes that affect the severity and
progression of CKD in humans.
MATERIALS AND METHODS
Strain comparison and generation of intercrosses
To examine systematically the effects of genetic background in a
model of CKD, we compared blood pressure, albuminuria, and
kidney injury scores in male and female wild-type 129S6 (Taconic)
and C57BL/6 (Jackson Laboratory, Bar Harbor, ME, USA) mice
subjected to subtotal nephrectomy. To define the inheritance pattern
of genetic modifiers of CKD, F1 (129S6C57BL/6) mice were
generated by mating male 129S6 and female C57BL/6 mice.
Genomic screen was performed using F2 mice generated from the
F1 (129S6 maleC57BL/6 female) intercrosses. Animals were bred
and maintained in the animal facility of the Durham Veterans
Affairs Medical Center under local and National Institutes of Health
guidelines.
Renal ablation
All mice were subjected to subtotal nephrectomy at 8 weeks of age.
Under general anesthesia with 1.5% isoflurane, the right kidney was
removed, and the blood supply to the upper half of the left kidney
was interrupted by ligation of the upper branch of the two main
branches of the left renal artery. The extent of renal infarction is
confirmed by visual inspection to ensure a uniform extent of kidney
injury in all mice. The uniformity of our surgical technique was also
assessed by determination of the percent atrophic area of the
remnant kidney by our pathologist who was masked to the
experimental conditions and crosses. Virtually all of the remnant
kidneys had an atrophic area ranging from 5 to 10% of the kidney,
with very few outliers of 15%. This suggests the lack of variability in
our model, and a good degree of reproducibility of the area of
infarction by our surgical technique. Mice are allowed to recover for
3 weeks after renal ablation before any training or phenotyping.
Phenotyping methods
From week 4 through 6 after subtotal nephrectomy, mice were
trained daily for blood pressure measurement using a computerized
tail-cuff system (Hatteras Instruments) as described previously.33,34
From week 7 through 10, systolic blood pressures were recorded at
least 5 days a week, 10–20 measurements each day. Training and
measurements were performed by the same operator at the same
time each day.
At week 12, mice were placed in metabolic cages35 and urine was
collected for 24 h and stored at 801C for later analysis. Urinary
albumin and creatinine concentrations were determined using
Exocell assays according to the manufacturer’s instructions (Exocell
Inc., Philadelphia, PA, USA). Albuminuria is expressed as A/C
(mg/mg) ratio as described previously.36
At week 13, mice were killed and the remnant kidneys were
removed and fixed with buffered formalin, embedded in paraffin,
sectioned, and stained with hematoxylin and eosin, and Masson’s
Trichrome (for collagen deposition). The slides were read and
interpreted by a renal immunopathologist without prior knowledge
of the treatment modality, the specific strain, or crosses. Renal
pathology was graded by standard methods for several morpho-
logical features, including glomerular inflammation, proliferation,
sclerosis (segmental or global), and mesangial changes. Interstitial
and vascular changes were also noted. Scores from 0 to 3 were
assigned for each of the features (e.g., glomerular inflammation was
graded as follows: 0, normal; 1, few inflammatory cells; 2, moderate
inflammation; and 3, severe inflammation), and then added
together to yield a final renal score. Scores for inflammation were
graded on the basis of both intensity and pattern of distribution
(e.g., focal, diffuse).
Data analysis
The values for each parameter within a group are expressed as
means7s.d. For comparisons between two groups, statistical
significance was assessed using an unpaired t-test. For comparisons
among three groups, ANOVA with Tukey’s multiple comparisons
tests was used to test for statistical significance.
Genome-wide scan and mapping
F2 mice were screened using 96 microsatellite markers (Applied
Biosystems, Foster City, CA, USA) spaced at approximately
15–20 cM intervals throughout the 19 mouse autosomes as we have
described previously.37 Genetic distances were obtained from public
databases. Genotyping errors were assessed by evaluation for
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adherence to Mendelian inheritance and for the presence of unlikely
double recombinant events or crossovers.
Linkage and QTL analyses were performed using Map Manager
QTXb20 software.38 For a quantitative trait, single locus association
tests39 were performed between each marker and the phenotype to
identify regions of interest. Simple interval mapping was performed
at 1-cM intervals. Permutation tests were performed on our data at
1-cM intervals for 10 000 permutations to establish linkage thres-
holds. Suggestive (P¼ 0.63), significant (P¼ 0.05), and highly
significant (P¼ 0.001) were established using guidelines suggested
by Lander and Kruglyak,40 and correspond to the 37th, 95th, and
99.95th percentiles, respectively. LRS value can be divided by 4.6 to
obtain the equivalent logarithm of the odds score.
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